Tom Boyd - Hepatiq, Private Partnering Interview at LSI USA ‘23

Transcription

Tom Boyd  0:05  

We're here today to really collaborate with investors and to present to them our cutting edge very exciting technology in the area of liver management, and connotates liver function. If you look at the current modalities right now for liver management, it includes biopsies, blood tests, or elastography, which essentially measures fibrosis in the liver, what we do is we quantitate the liver function. And if you use a car analogy, fibrosis is much like air in a gas tank. Quantitative liver function is like gas in the gas tank, the gas will tell you how far you're going to go. So it's very exciting, very compelling, the clinician gets a report that will actually project and tell that individual where this patient will be two, three years out. It's very unique, very different. It has its FDA cleared, it's covered by insurance. It's there's no hardware involved, it's simply a software update into the nuclear medicine departments in hospitals, or imaging centers throughout the country. So it's a very simple process. And it's easy for institutions to implement. We also give our prospects and clinicians this report by the 360 I research, which shows that liver management, the liver areas, an $8 billion market that's growing at 12% a year. So we're very excited about that we're clearly in the right space. In addition to that, it shows the various companies that are in the liver management business. There's companies such as Medtronic, Thermo Fisher, and they have bas right here. So we're very excited to be involved with those group of companies that says, Okay, we have something really exciting here to take a look at the patient's response. It's essentially they're put into a SPECT scanner, it's very much like an MRI. So the patient is probably familiar with the technology. Most patients have had MRIs done throughout their life. So it's very similar to that. It's, as I said, it's it's focused in nuclear medicine. So the patient is injected with a radioisotope to make the imaging more clear. So it takes about 40 minutes. There's there's nothing else involved for the patient except to sit still. That's first year for Hepatic at LSI. We're very excited to be here. We're actually local. We're up in Irvine. And so it's, it's exciting for us, and we definitely would come back again, we're actually starting to generate and promote the product from a marketing perspective, which is one of the main reasons we're here. In addition to raising money. We're at this meeting, to talk to investors who are looking between five and $10 million in investment in the company, or we're just looking forward to investors coming over and looking at our exciting technology and share with them something that's very exciting to us that should be very exciting to them to from an investment perspective.